BTIG analyst Ryan Zimmerman keeps a Neutral rating on Medtronic (MDT) after Centers for Medicare and Medicaid Services ...

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover ...

CMS proposed Medicare coverage for Medtronic's renal denervation therapy for high blood pressure, signaling a key step toward ...

On Thursday, the US Centers for Medicare & Medicaid Services (CMS) issued its proposal for covering radiofrequency- or ...

The patented method uses genetic markers and a weighted algorithm to assess the responsiveness to renal denervation.

Medtronic and Recor Medical both issued statements supporting new Medicare coverage for their respective renal denervation ...

The Centers for Medicare & Medicaid Services (CMS) issued a proposed decision memo for its National Coverage Analysis (NCA) ...

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced their support for ...

Medtronic is studying the use of its nitinol-enabled Symplicity Spyral renal denervation (RDN) catheter combined with hepatic ...

Medtronic reported that it has begun testing an expansion of its renal denervation approach for dropping stubbornly high blood pressure, by also treating vessels outside of the kidneys.&n | The ...

The United States Food and Drug Administration, in 2023, approved renal denervation—a catheter-based procedure that ablates the renal sympathetic nerves—as an adjunctive treatment for patients ...